Compugen Presents Pooled Analysis of COM701 in Platinum Resistant Ovarian Cancer at ESMO 2025

Compugen Ltd. will present a pooled analysis of COM701 in three Phase 1 trials for patients with platinum-resistant ovarian cancer at ESMO 2025. The analysis includes data from 60 evaluable patients and characterizes clinical benefit, progression-free survival, and safety profile. The presentation will include an additional year of follow-up data. Interim analysis results are expected at year-end 2026.

Compugen Ltd. will present a pooled analysis of COM701 in three Phase 1 trials for patients with platinum-resistant ovarian cancer at the European Society of Medical Oncology (ESMO) 2025 conference. The analysis, which includes data from 60 evaluable patients, characterizes clinical benefit, progression-free survival, and the safety profile of COM701. The presentation will also include an additional year of follow-up data. Interim analysis results are expected at year-end 2026 Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025^[1].

The pooled analysis supports the rationale for evaluating COM701 as maintenance therapy in earlier lines of treatment. The data suggests that COM701 is well-tolerated and shows consistent, durable responses, particularly in patients without liver metastases. These results provide a basis for further clinical evaluation of COM701 in earlier settings of platinum-sensitive ovarian cancer Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025^[1].

Compugen is currently conducting the MAIA-ovarian trial, which assesses COM701 monotherapy as maintenance treatment in relapsed platinum-sensitive ovarian cancer. The company expects to conduct an interim analysis of the MAIA-ovarian trial once data from approximately 60 participants are available. Sites have been activated in the U.S., Israel, and France, with enrollment rates supporting an anticipated interim analysis by year-end 2026 Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025^[1].

Compugen's President and CEO, Eran Ophir, highlighted the potential of COM701 to change the disease trajectory and improve progression-free survival for patients with platinum-sensitive ovarian cancer who are ineligible for or cannot tolerate additional maintenance treatment. The company's financial outlook supports its operating plans well into 2027, with cash reserves expected to sustain these plans Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025^[1].